What is the best process for vetting a fractional CRO for a medtech startup in 2027?

This vs. the common alternatives

The decision to bring in a fractional CRO is rarely made in isolation. Most medtech founders arrive at it after a specific trigger: the first commercial hire has plateaued, a Series A or B board has asked for a repeatable pipeline model, or an FDA clearance has landed and the company suddenly needs a go-to-market motion it has never built. Before you spend three weeks vetting fractional candidates, it is worth being honest about which of four paths actually fits your stage — because the vetting process changes depending on what you are comparing against.

Path one: hire a full-time CRO. A full-time commercial leader at a venture-backed medtech company typically commands a base in the mid-to-high six figures plus equity in the 0.5–2% range, and the search itself runs three to six months through a retained recruiter charging roughly a quarter to a third of first-year cash compensation. That is real money and real calendar time. The advantage is total ownership: the person is in every board meeting, owns hiring, and has skin in the game through a meaningful equity stake. The disadvantage for pre-revenue or early-revenue medtech is that you may be paying full freight for a leader whose primary job in year one is building a playbook rather than running a large team. If you have fewer than eight quota-carrying reps and less than a couple of million in annualized revenue, a full-time CRO is often over-hired for the actual work in front of you.

Path two: promote from within. Your best AE or your VP of Clinical Sales may already understand the product, the clinical evidence, and the buying committee better than any outsider. Promotion is fast and cheap and preserves institutional knowledge. It fails when the gap is not product knowledge but commercial architecture — forecasting discipline, territory design, contracting strategy, GPO and IDN navigation, RevOps instrumentation. Someone who has never built a commission plan or run a pipeline review cadence will learn on your dime, and in a regulated market the learning curve is expensive.

Path three: a consulting firm or agency retainer. Boutique medtech commercialization firms will sell you a market access assessment, a pricing study, or a channel strategy deliverable. These are genuinely useful for discrete questions. They are a poor substitute for a CRO because consultants produce recommendations, not owned outcomes. Nobody at the firm carries your number. If your problem is "we do not know what our reimbursement pathway means for pricing," a consultant is right. If your problem is "we have a number and nobody is hitting it," a consultant is wrong.

Path four: the fractional CRO. This is a senior commercial operator working two to four days a month, or one to three days a week, across a small portfolio of companies. In medtech the fractional model has specific merit because the scarcest skill — knowing how a hospital value analysis committee actually approves a new device, or how to structure a capital-plus-disposables deal against a fixed departmental budget — is knowledge you need continuously but not full-time. A fractional CRO who has sold through VACs at twenty hospital systems brings pattern recognition you cannot buy in a consulting deck and cannot grow internally in under two years.

The trade-off is attention and authority. A fractional leader is not in your building. They will miss things. They cannot personally run a weekly one-on-one with every rep. And if they are running four engagements, your crisis competes with three other crises. The entire point of a rigorous vetting process is to determine, before you sign, whether this specific person's pattern library maps to your specific regulated-market problem, and whether the engagement structure gives them enough surface area to actually change outcomes rather than just narrate them.

One more alternative deserves mention because medtech founders reach for it often: the advisor-with-equity. Someone respected in your therapeutic area agrees to advise for a small equity grant and a monthly call. This is cheap and can open doors. It is not a CRO. Advisors do not own forecasts, do not fire underperformers, and do not rebuild your CRM. Treat advisory relationships as a complement to commercial leadership, never as a replacement for it, and never let a well-known name on your advisory page substitute for someone accountable to a number.

How to choose between them

The choice hinges on three variables: how much commercial machinery already exists, how much regulatory and reimbursement complexity sits between your product and revenue, and how much runway you can commit before you need evidence of traction.

Start with a machinery audit. Ask concretely: Do we have a defined ideal customer profile at the account level, not the persona level? Do we have a documented sales stage definition with exit criteria? Do we have a CRM where opportunity data is trustworthy enough to forecast from? Do we have a compensation plan tied to the behaviors we actually want? If you answer no to three or more, you are pre-machinery, and a fractional CRO with a strong RevOps orientation is usually the highest-leverage hire — they build the chassis, then you hire a full-time leader to drive it.

Next, weigh regulatory complexity. A Class II device with an existing reimbursement code and an established predicate sells very differently from a Class III device requiring PMA, a novel CPT code application, and a multi-year evidence-generation strategy. The second scenario needs someone who has personally lived through a coverage-and-payment fight. That is a narrow candidate pool, and your vetting must probe it specifically rather than accepting general medtech credibility as proof.

Then consider runway. A fractional engagement typically needs two full quarters before you can fairly judge it — one to diagnose and rebuild, one to run the rebuilt motion. If you have under nine months of cash, be extremely careful: you may not have time to absorb a wrong hire and recover.

The four-stage vetting process itself is where most founders under-invest. Stage one is scoped intake: before you speak to a single candidate, write a one-page problem statement naming the specific commercial failure, the metrics that define success, the decision rights the fractional leader will hold, and the constraints they must work inside. Founders who skip this end up interviewing for vibes and hiring the most impressive résumé rather than the best fit.

Stage two is evidence-backed reference checking, and it must come earlier than most people run it. Conventional hiring puts references at the end. For fractional leaders, invert it — after the first conversation, ask for three named accounts where they held commercial responsibility, and call those references before the second interview. In medtech, ask references specifically: Did this person get us through a value analysis committee? Did their forecast hold within a reasonable band? Did they build something that survived after they left? A reference who can only offer character endorsement has told you the person was pleasant, not effective.

Stage three is the paid diagnostic. Pay a candidate a defined fee for a bounded two-week engagement in which they interview five to eight of your customers or prospects, review your pipeline data, and return a written commercial thesis. This is the single highest-signal step available to you. Résumés and interviews test articulation; a paid diagnostic tests thinking against your actual data. Run this with two finalists in parallel if budget allows — the comparison is enormously clarifying.

Stage four is the structured scorecard: six to eight outcomes with dates attached, reviewed at day 30, 60, and 90, with a pre-agreed exit ramp if the majority are missed.

Costs, timelines, and expected impact

Pricing for fractional commercial leadership varies widely with seniority, market scarcity, and time commitment, so treat any single number as a starting point rather than a benchmark. The structural options are what matter.

Monthly retainer is the most common structure. You buy a defined number of days per month — commonly two to six — at a fixed fee. This is predictable for cash planning and easy to budget against a board-approved operating plan. Its weakness is that it decouples payment from outcomes; a retainer that runs on autopilot for two quarters without a scorecard is how companies end up paying for a monthly strategy call.

Day-rate engagement prices each working day. It is flexible and good for uncertain scope, but it creates a mild incentive to expand days and makes forecasting spend harder. Use it for the diagnostic phase, then convert to a retainer once scope is known.

Retainer plus outcome bonus is the structure most aligned with a CRO role. A reduced base retainer is paired with a bonus tied to specific, measurable outcomes: a defined number of new health system accounts contracted, a documented reduction in sales cycle length, a pipeline coverage ratio achieved and sustained, or a forecast accuracy band held for two consecutive quarters. In medtech, be careful how you define these — tying a bonus purely to closed revenue can push a fractional leader toward discounting or toward pursuing accounts with fast procurement rather than strategic accounts with long VAC cycles. Blend a revenue metric with a leading-indicator metric.

Equity as partial compensation is common at seed stage. Small option grants with standard vesting and a cliff can align a fractional leader to long-term outcomes. Be disciplined: equity granted to a portfolio of fractional advisors and executives adds up quickly, and a fractional CRO who leaves after seven months should not walk with a meaningful stake. Use a shorter vest with a real cliff, and make continued vesting contingent on the engagement continuing.

On timelines, plan realistically. Sourcing and first conversations take two to four weeks if you are working referral networks rather than posting publicly. Reference checks add one week. The paid diagnostic is two weeks of their time but often three calendar weeks accounting for scheduling customer interviews. Contracting and onboarding take another week. From decision-to-search to first working day, six to nine weeks is a realistic range, and compressing it below four weeks almost always means skipping the diagnostic — which is the step you least want to skip.

Expected impact follows a predictable arc. In the first 30 days, output is diagnostic: a documented ICP at the account level, a rebuilt stage definition, a cleaned pipeline with opportunities re-scored against real criteria, and usually the uncomfortable discovery that qualified pipeline is smaller than the CRM claimed. Founders should brace for the forecast to go down before it goes up; a fractional CRO who does not shrink your reported pipeline in the first month is probably not scrubbing it honestly.

Days 30 to 90 produce structural change: a working forecast cadence, defined territory or account coverage, a revised comp plan, and often a hard conversation about one or two underperforming reps. Measurable revenue movement typically appears in months four through nine, because medtech sales cycles from first clinical champion contact through VAC approval and contracting frequently run six to eighteen months depending on device class, capital versus disposable model, and whether the buying system already has a competing product under contract.

Set board expectations accordingly. If your board expects revenue lift in 90 days from a device with a twelve-month sales cycle, the fractional CRO will be judged on an impossible standard and you will churn a good operator. Agree in advance that the 90-day scorecard measures machinery and leading indicators — qualified pipeline built, VAC submissions made, evaluation units placed, contracts in legal — not closed revenue.

Budget the surrounding costs too. A fractional CRO will almost always need RevOps support to implement what they design, and if you have no internal operations resource you should plan for either a part-time contractor or tooling spend. The most common failure pattern is hiring a strategic commercial leader with nobody to execute the CRM, reporting, and process changes they specify, then concluding after two quarters that "the fractional thing did not work" when the actual problem was an unstaffed implementation layer.

Implementation and handoff details

The engagement structure matters as much as the person. Write these into the agreement rather than assuming them.

Decision rights, explicitly. State what the fractional CRO can decide alone, what requires founder sign-off, and what is off-limits. At minimum they should own pipeline stage definitions, forecast methodology, the sales process, deal desk approval within a stated discount band, and performance management recommendations. Founders typically retain final say on hiring, firing, pricing floors, and any contract with a health system that carries unusual legal or compliance terms. Ambiguity here is the most common cause of a stalled engagement — a leader who must escalate every decision cannot lead.

Compliance boundaries, in writing. Medtech commercial leadership sits inside a regulatory perimeter that a generalist B2B CRO may not have internalized. The fractional leader must understand and operate within your policies covering interactions with healthcare professionals, transparency reporting obligations for payments and transfers of value, off-label promotion prohibitions, and any corporate integrity commitments your company carries. Require completion of your compliance training before day one, the same as any employee. Ask during vetting whether they have worked under an existing compliance program and how they handled a situation where a commercial instinct conflicted with a compliance rule — the quality of that answer separates operators who respect the perimeter from those who treat it as friction. Also confirm quality-system implications: if commercial staff handle complaints, adverse-event reports, or field feedback, the CRO's process design must route those correctly into your QMS rather than into a CRM note.

Conflict and confidentiality. Ask directly what other engagements they hold, in what categories, and get a written non-conflict commitment covering directly competitive devices and overlapping call points. Confirm whether their contract permits them to take a competing engagement during or shortly after yours, and negotiate a reasonable tail period. Also settle data handling: what CRM access they hold, what leaves your systems, and what happens to their working files at the end.

Cadence. Define the operating rhythm in the contract: a weekly forecast and pipeline review, a biweekly working session with the founder or CEO, a monthly written update, and presence at board meetings if you want them there. Fractional engagements decay when the cadence is informal — the days quietly compress into a monthly call and the leadership evaporates.

The handoff package. From day one, contract for artifacts, not just advice. Specify in writing what the fractional CRO must leave behind: documented ICP and account tiering, sales stage definitions with exit criteria, the forecast model and its assumptions, territory and account coverage maps, the compensation plan and its rationale, call scripts and discovery frameworks specific to clinical and economic buyers, VAC submission templates and the evidence packet that supports them, competitive battlecards, and a written state-of-the-business memo. These live in your systems, not theirs. A fractional engagement that ends with knowledge only in one person's head has transferred nothing.

Internal ownership. Assign an internal counterpart from the start — often a senior AE, a RevOps analyst, or an operations-minded founder. This person shadows the fractional leader, executes between visits, and becomes the continuity layer. When the engagement ends or converts to a full-time hire, they are the bridge. Without this, every fractional day is spent re-establishing context.

Onboarding to the clinical reality. Require field time in the first three weeks: observe at least two cases or procedures where permitted, sit in on a value analysis committee submission if one is pending, and ride along with reps into at least four accounts. A commercial leader who has only seen your product in a deck will design a process that does not survive contact with a hospital.

Exit ramps and conversion. Write both. The exit ramp should be a 30-day notice provision either direction after the 90-day mark, with the handoff package as a delivery condition. The conversion path matters too: if the engagement works, you may want this person full-time or as a formal advisor. Address in advance how equity, notice, and any recruiter-style conversion fee are handled, so a good outcome does not turn into a negotiation fight.

What to watch for once running. Three warning signs recur. First, the fractional leader spends their days in strategy documents rather than in deals and with reps — commercial leadership is a contact sport, and a leader who never touches a live opportunity is not leading. Second, the forecast stops moving; a pipeline that looks identical month over month means the scrubbing stopped. Third, your internal counterpart stops being included, which signals the knowledge transfer has quietly ended. Any of these should trigger a direct conversation at the next biweekly session rather than a slow drift toward the 90-day review.

Finally, instrument the engagement. The RevOps discipline that a good fractional CRO brings should be applied to the engagement itself: track days used against days contracted, log which scorecard items are green, amber, and red, and keep a written record of decisions made and their rationale. When the board asks whether the fractional model is working, you want evidence rather than impressions.

Related questions

How long should a fractional CRO engagement run before you judge it?

Two full quarters minimum. The first 90 days produce machinery — ICP, stages, forecast method, comp plan. Revenue movement in medtech typically appears months four through nine given six-to-eighteen-month sales cycles. Judge day 90 on leading indicators, not closed bookings.

Should the paid diagnostic be run with more than one candidate?

Yes, if budget allows. Running two finalists in parallel on the same bounded scope produces a direct comparison of how each thinks against your actual pipeline data. It is the clearest differentiator you will get, and far more informative than a third interview round.

What compliance training does a fractional commercial leader need?

The same program your employees complete, before day one: HCP interaction policy, transparency reporting obligations, promotional review requirements, off-label prohibitions, and complaint or adverse-event routing into the quality system. Contractor status does not reduce the company's exposure.

Can a generalist B2B SaaS CRO succeed in medtech?

Sometimes, but the gap is real. Hospital buying involves value analysis committees, clinical champions, economic buyers, GPO contracts, and reimbursement dependencies that have no SaaS analog. If you hire a generalist, pair them with a medtech-native advisor and extend the ramp expectation.

What should the handoff package contain?

Documented ICP and account tiering, stage definitions with exit criteria, the forecast model and assumptions, coverage maps, the comp plan and rationale, clinical and economic buyer discovery frameworks, VAC submission templates, battlecards, and a written state-of-the-business memo — all stored in your systems.

FAQ

How many days per month is right for a fractional CRO at an early-stage medtech company?

Most engagements land between two and six days per month, with the higher end common during the first quarter when diagnosis and rebuild work is heaviest. Under two days a month, the role degenerates into advisory — there is not enough surface area to own a forecast or manage performance. Above six days a month, you should ask whether you are approaching the economics of a part-time or full-time hire anyway. A common structure ramps down: heavier in the first 90 days, lighter once the machinery is built and an internal counterpart is executing.

What is the single highest-signal step in the vetting process?

The paid diagnostic. Interviews test how well someone articulates a commercial philosophy; a bounded paid engagement tests how they think against your specific pipeline, your specific customers, and your specific regulatory constraints. A candidate who returns a thesis naming your real bottleneck — even if the answer is uncomfortable — has demonstrated more than any reference call can. It also reveals working style, responsiveness, and whether they can produce a written artifact under a deadline.

How do I check references for someone who worked fractionally rather than full-time?

Ask for three named accounts where they held commercial responsibility, and speak with the founder or CEO at each, not a peer. Push past character endorsement with specifics: What number did they own? Did the forecast hold? Did anything they built survive their departure? Did they get you through a value analysis committee, and what did that submission look like? If a candidate cannot produce references who can answer at that level of detail, that itself is the finding.

What does a fair 90-day scorecard look like for a medtech fractional CRO?

Six to eight items, weighted toward machinery and leading indicators rather than closed revenue. Typical entries: documented account-level ICP delivered, sales stages redefined with exit criteria, CRM pipeline re-scrubbed with a defensible qualified number, forecast methodology in place and run for two cycles, a defined number of VAC submissions or evaluations initiated, comp plan revised, and an internal counterpart onboarded. Agree the list before signing, review at day 30 and 60, and decide at day 90.

How should equity be handled for a fractional executive?

Use a small grant with a shorter vest and a real cliff, with vesting contingent on the engagement remaining active. This protects the cap table if the fit is wrong while still aligning someone who stays. Have counsel review the structure — contractor equity, its tax treatment, and its interaction with your existing plan differ meaningfully from employee grants, and medtech companies with future strategic-acquirer diligence in mind should keep the cap table clean.

What is the most common reason a medtech fractional CRO engagement fails?

An unstaffed implementation layer. The fractional leader designs the process, the CRM changes, the reporting, and the comp plan — and nobody inside the company executes them between visits. Two quarters later the founder concludes the model does not work, when the actual gap was RevOps capacity. Before signing, name the person or contractor who will implement, and budget for them.

Sources

• https://www.fda.gov/medical-devices — FDA Medical Devices center: device classification, 510(k) and PMA pathways.
• https://www.cms.gov/medicare/coverage — CMS coverage policy and the national/local coverage determination process.
• https://www.ama-assn.org/practice-management/cpt — AMA CPT coding resources, including new code applications.
• https://oig.hhs.gov/compliance/ — HHS Office of Inspector General compliance program guidance for healthcare and manufacturers.
• https://openpaymentsdata.cms.gov/ — CMS Open Payments, the transparency reporting database for payments to physicians and teaching hospitals.
• https://www.advamed.org/ — AdvaMed, the medical device industry association, including its Code of Ethics on HCP interactions.
• https://www.nih.gov/health-information — NIH health information, useful background for clinical evidence context.
• https://hbr.org/topic/subject/sales — Harvard Business Review sales and go-to-market research archive.
• https://www.sec.gov/edgar/search/ — SEC EDGAR full-text search, useful for reading public medtech companies' commercial disclosures.
• https://www.ftc.gov/business-guidance — FTC business guidance on advertising, endorsements, and competitive claims.

Related on PULSE

• How to structure a 90-day scorecard for a fractional revenue leader
• What a paid diagnostic engagement should deliver before you sign a retainer
• How hospital value analysis committees change B2B sales cycle design
• Building a RevOps implementation layer for a fractional commercial leader
• Forecasting discipline for long-cycle, reimbursement-dependent revenue
• When to convert a fractional CRO into a full-time hire